Pharmaxis Announces US$40 million Financing Agreement with NovaQuest

31st Jan 13

Release Date: 31/01/2013 9:15am

Pharmaceutical company Pharmaxis Ltd (ASX: PXS) is pleased to announce the signing of a Financing Agreement with NovaQuest Pharma Opportunities Fund III, LP (NovaQuest) under which NovaQuest will invest up to US$40 million to support the continued development, manufacturing and commercialisation of Bronchitol for cystic fibrosis in the EU and US. 


Read full media release - pdf

Categories: News and Media